Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia
Irish biopharmaceutical company Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic hypersomnia (IH).
The double-blind, placebo-controlled Vibrance-3 trial is expected to enrol a total of around 96 IH patients across sites in Australia, Europe and the US.
Subjects will be randomised and given either 10mg, 14mg or 18mg of the therapy, or a placebo, once a day for eight weeks.
Alkermes said that based on the dose level, the trial's primary endpoint will evaluate if the subjects taking the therapy experience a reduction in sleepiness against those who are taking only a placebo.
This will be determined as per the measure of changes in the Epworth Sleepiness Scale (ESS) score.
Subjects who complete the trial will be eligible to continue in an open-label, long-term safety trial.
Alkermes Research & Development executive vice-president and chief medical officer Craig Hopkinson said: "The initiation of Vibrance-3 represents an important step forward for the ALKS 2680 development programme as we seek to advance a potential new treatment option for people living with idiopathic hypersomnia.
"The Vibrance-3 Phase II study builds on encouraging data from our phase Ib, proof-of-concept study of ALKS 2680 in patients with IH, and we look forward to further characterising its safety and efficacy profile in this patient population."
ALKS 2680 is an oral, selective orexin 2 receptor (OX2R) agonist being developed as a once-a-day treatment for narcolepsy type I and II, as well as IH–chronic, neurological conditions marked by 'excessive' daytime sleepiness.
The ongoing Phase II studies, Vibrance-1 and Vibrance-2, are assessing the therapy's efficacy and safety in adults with narcolepsy type I and II respectively.
Last year, Alkermes announced positive topline data from the narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) cohorts of a Phase Ib trial of ALKS 2680.
"Alkermes begins Phase II trial of drug candidate for idiopathic hypersomnia" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
21 hours ago
- CBS News
Fire at Shell cracker plant in Beaver County forces evacuation of multiple employees
A spokesperson for the Pennsylvania Department of Environmental Protection said a fire at the Shell cracker plant in Beaver County forced the evacuation of multiple employees and potentially released chemicals into the community. Anita White and Eli Matich worry about what could be in the air outside their home in Potter Township, just miles away from the plant. "It just feels scary, because you don't really know how it's impacting your health," White said. "When they built it, it was meant for job employment, help boost Beaver County. But instead, it's kind of been more negative than positive, it seems like," Matich said. It was just two days ago when smoke appeared to be billowing out of the facility, caused by what the state DEP calls a fire. It happened Wednesday afternoon at ethane cracking furnace #5. The DEP spokesperson said Shell reported that 15 employees were evacuated, and one person suffered a minor heat-related injury. KDKA obtained a photo showing a mangled furnace inside the complex. A Shell employee told KDKA that the damage is so bad it could result in them tearing it down and rebuilding. "It's definitely concerning," Matich said. The DEP spokesperson said it resulted in the "possible release of an unknown amount of 1,3-butadiene and benzene" in the air, and that the furnace "was not in production at the time." The agency added that an emergency response team member conducted an initial assessment at the plant and did not see any visible emissions or unintended releases of them due to a malfunction or other problem, along with any unpleasant smells. Also, their "air monitor did not register any emissions above zero, which means there weren't any air pollutants that lingered related [to] the fire." "We're always trying to eat healthy and be clean, but then we have these chemicals that are going into the air. So, it kind of feels like, all right, what's the point?" White said. Environmental experts describe what may have been released this week as cancer-causing chemicals. Since Shell started operating here in late 2022, it's faced several malfunctions and millions of dollars in fines. Shell did not disclose the potential release of chemicals in a Facebook post to the public, but a spokesperson told KDKA they informed the Nuclear Regulatory Commission, and "will submit the [investigation] findings, as required, to the Pennsylvania Emergency Management Agency (PEMA) and the Local Emergency Planning Commission (LEPC)." As for White and Matich, for the time being, they'll be staying where they are. "Until the housing market gets a bit better, so we can move a little farther away," White said. The DEP spokesperson said Shell is continuing to investigate and that the agency will ensure the company complies with environmental regulations for the health and safety of the community.
Yahoo
2 days ago
- Yahoo
Brand-new SpaceX Crew Dragon capsule arrives at pad for June 10 astronaut launch (photo)
When you buy through links on our articles, Future and its syndication partners may earn a commission. The Crew Dragon capsule that will fly SpaceX's next astronaut mission has arrived at the launch pad. That flight, called Ax-4, is scheduled to lift off atop a Falcon 9 rocket on June 10 from historic Pad 39A at NASA's Kennedy Space Center in Florida. SpaceX just took a step toward meeting that timeline: It has delivered the Dragon to Pad 39A's hangar, the company announced via X on Thursday (June 5). That capsule — a brand-new vehicle, with no flights yet under its belt — will carry four people to and from the International Space Station (ISS) for the Houston-based company Axiom Space. It will be Axiom's fourth such mission, which explains the Ax-4 name. Ax-4 will be commanded by Peggy Whitson, a former NASA astronaut who currently serves as Axiom's director of human spaceflight. She holds the American record for most total time spent in space: 675 days. Whitson's three crewmates are India's Shubhanshu Shukla, who is Ax-4's pilot, and mission specialists Sławosz Uznański and Tibor Kapu. Uznański, a European Space Agency astronaut, is from Poland, and Kapu is from Hungary. Nobody from either country, or from India, has ever lived aboard the ISS before, so Ax-4 will break new ground. Related stories: — SpaceX Dragon carrying Ax-3 astronauts splashes down in Atlantic to end longest private spaceflight for Axiom Space — Axiom Space: Building the off-Earth economy — Axiom Space eyes the moon while continuing to dream big in Earth orbit The Ax-4 astronauts are expected so spend two weeks living and working on the ISS, conducting about 60 different science experiments. Then they'll head back down to Earth, eventually splashing down in the Pacific Ocean. Axiom's first astronaut mission, Ax-1, launched in April 2022. Ax-2 and Ax-3 followed in May 2023 and January 2024, respectively. All have used SpaceX hardware to get to and from the ISS.
Yahoo
2 days ago
- Yahoo
Measles in Iowa: What parents, and the public, should know about the first case in nearly six years
DES MOINES, Iowa — The first confirmed case of measles in Iowa since 2019 was announced by the state's Department of Health and Human Services on May 23, 2025. However, specific details on the patient and potential exposure of additional residents have been limited. 'Through our thorough investigation, it was learned this individual had traveled outside of the state of Iowa,' said HHS's Director of Communications Alex Murphy via email to WHO 13's Katie Kaplan. 'A thorough investigation has been completed. Public health officials will be reaching out to identified contacts, and no widespread public exposure is anticipated.' While the initial release from HHS on the confirmed Iowa case stated the patient was an unvaccinated adult, Murphy added that any further information about the specifics of the case was 'protected from disclosure under Iowa Code 139A.3(3).' While it is unconfirmed which medical facility the patient was treated at, WHO 13 was able to view internal messages from Central Iowa medical networks that were sent to area medical professionals. One noted that the Central Iowa resident may have recently traveled to Mexico and Texas. HHS confirmed to WHO 13 that the patient traveled internationally, but did not specify where. The announcement about the highly contagious viral illness that is spread through the air when an infectious person coughs, sneezes, or breathes was made late in the workday on a Friday afternoon before the Memorial Day weekend. 'Measles is as scary as it sounds because it's so contagious,' said Dr. Daniel Pelzer, a Pediatrician with the Iowa Clinic. 'It is 10 to 12 times more contagious than a normal flu virus that spreads around every year. And for that reason, it's important for us to get ahead of that so that the unvaccinated or under-vaccinated in our community aren't at risk.' Pelzer said local physicians have been following the growing number of cases across the U.S. and have been preparing for a local case for months. He added that the case, which HHS said tested positive at the State Hygienic Laboratory, activated the plans that include vetting patients through their symptoms, limiting exposure to the public, and the potential use of hazmat, or PPE (Personal Protective Equipment) gear, for health providers. He said the first step the public should take if they believe they have the measles, or have been exposed to the illness, is to pick up the phone. Des Moines police release name of motorcyclist killed in crash 'For parents, if you think you have a case of measles in your house, or a known exposure, call us. Again, measles is so contagious that if it would arrive in our office, it would grind the entire clinic to a halt because of the density of airborne virus transmission,' he said. According to the HHS, about 1 in 10 people in the U. S. who get measles will be hospitalized, and 1 to 3 out of 1,000 children with measles will die even with good medical care. Measles was declared 'eliminated' from the United States in 2000, according to the CDC. This meant the absence of the continuous spread of disease was greater than 12 months. Most people who have been fully vaccinated against the illness do not need booster shots and are 'less susceptible' to contracting it, Pelzer said. However, he said he has watched as immunizations in local children have fallen in recent years, specifically since the Pandemic. 'Herd immunity, about 95%, is what we need to effectively, in communities, limit the spread of measles,' he said. 'In the last decade that I've been a pediatrician in this town, I've seen that rate decrease from 95%, which is our safe rate, down to closer to 90% by our best guesses.' Measles symptoms include a high fever, cough, and runny nose, followed by a red rash most often found on the face and arms. Tiny white bumps may also develop inside the mouth. The illness can lead to swelling of the brain and other complications. 'The best time to prevent measles is before an exposure occurs, and the best tool we have is getting the measles, mumps, and rubella (MMR) vaccine,' said Dr. Robert Kruse, State Medical Director, via a written statement provided by the HHS. 'Getting vaccinated not only protects you but also protects people in your community who can't get vaccinated, like infants too young to begin the series and those who are immunosuppressed.' If you think you have been exposed to a measles case and have symptoms, call your medical provider or nearest emergency room ahead of time and tell them that you have been exposed to measles and have symptoms before arriving. Measles symptoms begin to appear 7-to-21 days after exposure. As of June 5, nearly two weeks after the announcement of the case, the HHS told WHO 13 that there have been no other confirmed cases of measles in the state of Iowa. Iowa News: Measles in Iowa: What parents, and the public, should know about the first case in nearly six years WHO 13 Farm Report: Thursday, June 5 Motorcyclist killed after being hit by semi in Floyd County identified Forecast: Mild temps and tiny rain chances WHO 13 Farm Report: Wednesday, June 4 Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
